Characterisation, management, and outcomes of New Delhi metallo-β-lactamase-producing Escherichia coli: A case series

Document Type

Article

Publication Date

1-1-2025

Publication Title

J Glob Antimicrob Resist

Abstract

OBJECTIVE: New Delhi metallo-β-lactamase (NDM)-producing carbapenem-resistant Enterobacterales (CRE) is a globally growing threat. We sought to describe the microbiology, management and outcomes of patients with this infection at our facility.

METHODS: This is a descriptive case series of patients with NDM-producing Escherichia coli isolated from culture in Detroit between July 2021 and February 2023. Demographics, risk factors, clinical characteristics, management and outcomes were described.

RESULTS: Nine patients were included in the study. Most patients were female with a median age of 67 years. Hepatobiliary disease accounted for 90% of underlying conditions. Nearly all patients had prior antibiotic exposure and the most common specimen source was intra-abdominal fluid. Three patients were not treated due to colonisation; among those treated, the majority received trimethoprim-sulfamethoxazole. The median treatment duration and length of stay were 7 and 15.5 days, respectively. Six (67%) patients survived.

CONCLUSIONS: This report describes a large case series of NDM-producing E. coli infection. Patients with significant comorbidities remain at high risk for CRE infection. Antibiotic options for the treatment of NDM organisms are very limited; new and effective therapies are urgently needed.

Medical Subject Headings

Humans; beta-Lactamases; Female; Escherichia coli; Male; Aged; Escherichia coli Infections; Middle Aged; Anti-Bacterial Agents; Aged, 80 and over; Microbial Sensitivity Tests; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Treatment Outcome; Carbapenem-Resistant Enterobacteriaceae; Michigan

PubMed ID

39631625

Volume

40

First Page

42

Last Page

46

Find It @ Sladen

Share

COinS